CVIT 2021: Dr. Rahul P. Sharma, Interventional Cardiologist and Director of Structural Interventions at Stanford Medical Center, shares his experience with FFRangio, including important clinical evidence and the benefits of FFRangio for routine clinical practice.
Applicability of FFRangio in Serial Lesions Diffuse Disease
Dr. Carlos Collet Bortone
the Cardiovascular Center OLV AALST, Belgium
FFRangio in Routine Clinical Practice US Experience
Dr. Rahul P. Sharma
Stanford University Medical Center, California
“FFRangio has the potential to eventually replace wire-based FFR measurement and substantially increase physiological coronary lesion assessment in the catheterization laboratory, thereby leading to improved patient outcomes”